Previous 10 | Next 10 |
Minerva Neurosciences press release ( NASDAQ: NERV ): Q2 GAAP EPS of -$1.63. Cash, cash equivalents and restricted cash as of June 30, 2022 and December 31, 2021 were approximately $49.9 million and $60.9 million, respectively. For further details see: Minerva Ne...
WALTHAM, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for...
Hyzon Motors ( HYZN ) -36% after disclosing operational inefficiencies, financial issues . Helius Medical Technologies ( HSDT ) -30% . Quoin Pharmaceuticals ( QNRX ) -23% . Chembio Diagnostics ( CEMI ) -18% on Q2 earnings release . ...
Gainers: InVivo Therapeutics Holdings ( NVIV ) +164% . ChemoCentryx ( CCXI ) +109% . Minerva Neurosciences ( NERV ) +104% . Missfresh ( MF ) +66% . Society Pass ( SOPA ) +49% . Greenpro Capital ( GRNQ ) +48% . Yel...
Gainers: Global Blood Therapeutics ( GBT ) +33% . Yellow ( YELL ) +27% . Pactiv Evergreen ( PTVE ) +17% . Minerva Neurosciences ( NERV ) +13% . MercadoLibre ( MELI ) +13% . Losers: Poseida Therapeutics ( PSTX ) ...
Minerva Neurosciences press release (NASDAQ:NERV): Q1 GAAP EPS of -$0.23 misses by $0.05. Cash, cash equivalents, and restricted cash as of March 31, 2022 and December 31, 2021 were approximately $55.0 million and $60.9 million, respectively. For further details see: Minerva Neuroscienc...
WALTHAM, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the ...
Biopharmaceutical company Minerva Neurosciences (NASDAQ:NERV) has received the official meeting minutes from the March type C meeting with the U.S. FDA regarding the development of the company's compound roluperidone to treat negative symptoms in schizophrenia. The meeting's primary purp...
WALTHAM, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company developing therapies to treat central nervous system (CNS) disorders, announced today that it has received the official meeting minutes from the Type...
Minerva Neurosciences press release (NASDAQ:NERV): Q4 GAAP EPS of -$0.50 misses by $0.31. Cash, equivalents and restricted cash as of December 31, 2021 were approximately $60.9 million, as compared to $25.5 million at December 31, 2020. For further details see: Minerva Neurosciences GAA...
News, Short Squeeze, Breakout and More Instantly...
Minerva Neurosciences Inc Company Name:
NERV Stock Symbol:
NASDAQ Market:
Minerva Neurosciences Inc Website:
BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the first q...
A look at the top 10 most actives in the United States SoundHound AI Inc. (SOUN) rose 19.3% to $6.86 on volume of 301,330,136 shares Canoo Inc. (GOEV) rose 8.3% to $0.1138 on volume of 118,801,751 shares Ault Alliance Inc. (AULT) rose 19.1% to $0.4642 on volume of 117,184,555 shares Mar...